2021 CMSC Annual Meeting

Late Breaking-Disease-modifying therapy

Late Breaking-Disease-modifying therapy

Interim Results of Open-Label Multicenter Phase 4 Study Assessing Immune Response to Influenza Vaccine in Patients with Relapsing Multiple Sclerosis Treated with Ofatumumab

Background: Vaccinations comprise an important component of MS management. Data are needed regarding whether ofatumumab (OMB) impacts...

Read More

Late Breaking-Disease-modifying therapy

Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab

Background: Ofatumumab, a fully human anti-CD20 monoclonal antibody, is approved for the treatment of relapsing multiple sclerosis (RMS) in...

Read More

Late Breaking-Disease-modifying therapy

Dimethyl Fumarate Is Associated with Lower Rates of Infection and Lower Infection-Related Healthcare Costs When Compared with Ocrelizumab

Background: Infections in people with multiple sclerosis (PwMS) may have a detrimental effect on disease progression, risk of...

Read More

Late Breaking-Disease-modifying therapy

US Real World Experience Switching from Infusion and S1P Therapies to Cladribine Tablets: A Single Center Study

Background: Multiple sclerosis (MS) is a chronic neurological disorder and a major cause of disability in young adults. Cladribine tablets...

Read More

Late Breaking-Disease-modifying therapy

Early Experience with Cladribine Tablets in an Aging Patient Population

Background: Cladribine, a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, may disrupt the central immune cascade...

Read More

Late Breaking-Disease-modifying therapy

Humoral and T-Cell Responses to Sars-Cov-2 Vaccination in Multiple Sclerosis Patients Treated with Ocrelizumab

Background: The COVID-19 epidemic raises important questions about the efficacy of vaccines for people treated with ocrelizumab (OCR), an...

Read More

Late Breaking-Disease-modifying therapy

Variables Affecting Disease Modifying Therapy Adherence and Impact of Adherence on Multiple Sclerosis Patients (Egyptian experience)

Background: Multiple sclerosis (MS) is a chronic immune-mediated neurological disease affecting mainly young adults. MS patients are more...

Read More

Late Breaking-Disease-modifying therapy

B-Cell Depleters Attenuate the Humoral Response to Sars-Cov-2 Vaccines in Multiple Sclerosis Patients: A Case-Control Study

Background: B-cell depleting agents are FDA approved for the treatment of RRMS (ocrelizumab (OCR) and ofatumumab (OFA)) and PPMS...

Read More

Late Breaking-Disease-modifying therapy

Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment

Background: Natalizumab 4-week dosing (Q4W) with 300 mg is approved for treatment of relapsing-remitting multiple sclerosis. Dosing...

Read More

Late Breaking-Disease-modifying therapy

Sustained B-Cell Depletion By Inebilizumab Is Associated with Decreased Disease Activity in Aquaporin-4 Seropositive Neuromyelitis Optica Spectrum Disorder

Background: Inebilizumab is a humanized, affinity-optimized, anti-CD19 monoclonal antibody approved in Japan, South Korea and the USA to...

Read More